• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Furovenir
    / BioAvenir

    Active Ingredient
    Furosemide 250 mg/25 ml

    Status in Israel

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft


    50 x 250 mg/25 ml

    not in the basket chart 21187 6471

    Related information


    Duration of the treatment will depend on usage and is determined by the doctor for each individual. For adults, the maximum recommended dose is 1,500 mg daily, although it may reach 2,000 mg in exceptional cases. For children, the maximum recommended daily dose of FuroVenir for parenteral administration is 1 mg of furosemide per each kilogram of body weight, up to a maximum of 20 mg. Treatment is to be switched to the oral route as soon as possible. FuroVenir 250mg solution for IV infusion should be injected or infused slowly by intravenous route, at a rate not exceeding 4 mg per minute. In patients with severe kidney problems (serum creatinine >5 mg/dl), it is recommended that the rate of infusion does not exceed 2.5 mg per minute. It should not be administered in the form of intravenous bolus. It should be infused using only infusion pumps that control volume or speed in order to avoid a possible risk of accidental overdose. FuroVenir 250 mg solution for IV infusion should not be Mixed in the same syringe or infused together with other medicines. The suitable diluent is isotonic saline solution. No acid solutions should be used. The pH of the solution to be infused should be neutral or lightly alkaline. It is recommended that the ready-to-use solution be administered as soon as possible. FuroVenir should never be infused together with other medication in the same intravenous fluid.
    Use in children: Parenteral administration is contraindicated for infants and children under the age of 15; this may be carried out only in cases involving a threat to life.


    Oliguria in acute or chronic renal failure. For use only in patients with extremely reduced glomerular filtration.


    Hypersensitivity to furosemide or sulphonamides (cross-sensitivity exists between the two). Pregnancy and lactation. Should not be given in anuria or in renal failure due to nephrotoxic or hepatoxic drugs, nor in renal failure associated with hepatic coma. Should not be given to patients with Addison’s disease or pre-existing hypercalcemia.

    Special Precautions

    Fluid balance should be carefully monitored. May cause profound diuresis, resulting in fluid and electrolyte depletion. Serum electrolytes (especially sodium, potassium, chloride and bicarbonate) should be determined, and abnormalities corrected or the drug withdrawn. If increasing azotemia and oliguria occur during treatment of progressive renal disease, the drug should be discontinued.Should be avoided in anuric patients except as a single trial dose in acute anuria in the absence of obstruction.Caution should be excercised in patients with impaired hepatic function or renal impairment. Sudden alteration of fluid and electrolyte balance in patients with cirrhosis may precipitate hepatic coma, therefore strict observation is necessary during the period of diuresis.Patients should be regularly observed for the possible occurrence of blood dyscrasias, liver damage or other idiosyncratic reactions.Period checks on urine and blood glucose should be made in diabetics and those suspected of latent diabetes. Increases in blood glucose and alterations in glucose tolerance test, with abnormalities of the fasting and 2-hour post-prandial sugar have been observed and rare cases of precipitation of diabetes mellitus have been reported.May lower serum calcium levels and rare cases of tetany have been reported. Accordingly, calcium should be determined periodically.Patients with prostatic hypertrophy or impaired micturition have an increased risk of developing acute retention.Care is advised when prescribing to patients with either gout or porphyria.
    For full details see prescribing information.

    Side Effects

    As with all medicines, FuroVenir 250 mg solution for IV infusion may have adverse effects.Like other diuretics, the prolonged administration of this medicament may increase the elimination of sodium (hyponatremia), chlorine (hypochloremic alkalosis) and of water as a result of this. It may also heighten the loss of potassium (hypopotassemia), calcium, and magnesium. Such alterations present themselves with intense thirst, headaches, confusion, muscle cramps, painful muscular contractions especially in the limbs (tetany), muscle weakness, alterations in the cardiac rhythm, and gastrointestinal symptoms.In older patients in particular, FuroVenir 250 mg solution for IV infusion may result or contribute to the occurrence of a reduction in total blood volume, dehydration, and coagulation alterations (thrombosis). FuroVenir may cause or aggravate discomfort in patients with difficulties to urinate; also, acute urinary retention may occur and cause possible secondary complications. On rare occasions, cases of kidney problems that might result from an allergy-type renal reaction (interstitial nephritis) have been reported.
    For full details see prescribing information.

    Drug interactions

    Furosemide -induced hypokalaemia may induce potentially fatal cardiac arrhythmias during treatment with cardiac glycosides or drugs that prolong the QT.
    For full details see prescribing information.

    Pregnancy and Lactation

    Animal teratology studies indicate that furosemide may cause foetal abnormalities. Therefore, furosemide should only be used in women of child-bearing age when appropriate contraceptive measures are taken or if the potential benefits justify the potential risks to the foetus. Furosemide is excreted in breast milk and breast-feeding should be discontinued if treatment is essential.


    Symptoms: Overdose with furosemide may lead to excessive loss of water and electrolytes. Severe potassium loss may cause serious cardiac arrhythmias.
    Treatment: Restoration of fluid and electrolytes balance by administration of sodium chloride and water, intravenously if necessary.

    Reig Jofre SA, Spain
    Licence holder